CD44的生物特征及在恶性肿瘤中的研究进展
Biological Characterization of CD44 and Progress in Malignant Tumors
DOI: 10.12677/acm.2024.1461940, PDF,   
作者: 田思岳*, 范志勤#：新疆医科大学附属肿瘤医院日间病房(三病区)，新疆 乌鲁木齐
关键词: CD44；恶性肿瘤；癌症干细胞；预后；CD44； Cancer； Cancer Stem Cells； Prognosis
摘要: CD44是一种复杂的跨膜糖蛋白，在肿瘤干细胞上过度表达。CD44表达失调与肿瘤发生和发展有关。CD44参与多种重要信号通路的调控，与肿瘤增殖、侵袭、转移和治疗耐药密切相关。CD44过度表达抑制化疗药物在多种癌症中的细胞毒作用。因此，CD44可以作为癌症患者的不良预后标志物。CD44过度表达为化疗耐药患者的治疗干预提供新的分子靶点。本篇综述重点概述CD44的结构功能，CD44在肿瘤细胞干性和肿瘤发生发展中的作用，及与癌症患者预后的关系。
Abstract: CD44 is a complex transmembrane glycoprotein that is overexpressed on tumor stem cells. Dysregulated CD44 expression is associated with tumorigenesis and progression. CD44 is involved in the regulation of multiple important signaling pathways and is closely related to tumor proliferation, invasion, metastasis, and therapeutic resistance. CD44 overexpression inhibits the cytotoxic effects of chemotherapeutic agents in multiple cancers. Therefore, CD44 can be used as a poor prognostic marker for cancer patients. CD44 overexpression provides new molecular targets for therapeutic intervention in chemotherapy-resistant patients. This review focuses on an overview of the structure and function of CD44, the role of CD44 in tumor cell stemness and tumorigenesis and development, and its relationship to the prognosis of cancer patients.
文章引用：田思岳, 范志勤. CD44的生物特征及在恶性肿瘤中的研究进展[J]. 临床医学进展, 2024, 14(6): 1490-1494. https://doi.org/10.12677/acm.2024.1461940

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Cao, W., Chen, H., Yu, Y., Li, N. and Chen, W. (2021) Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chinese Medical Journal, 134, 783-791. [Google Scholar] [CrossRef] [PubMed]
[3] Hassn Mesrati, M., Syafruddin, S.E., Mohtar, M.A. and Syahir, A. (2021) CD44: A Multifunctional Mediator of Cancer Progression. Biomolecules, 11, Article No. 1850. [Google Scholar] [CrossRef] [PubMed]
[4] Skandalis, S.S. (2023) CD44 Intracellular Domain: A Long Tale of a Short Tail. Cancers, 15, Article No. 5041. [Google Scholar] [CrossRef] [PubMed]
[5] Cirillo, N. (2023) The Hyaluronan/CD44 Axis: A Double-Edged Sword in Cancer. International Journal of Molecular Sciences, 24, Article No. 15812. [Google Scholar] [CrossRef] [PubMed]
[6] Chen, S., Zhang, S., Chen, S. and Ma, F. (2023) The Prognostic Value and Immunological Role of CD44 in Pan-Cancer Study. Scientific Reports, 13, Article No. 7011. [Google Scholar] [CrossRef] [PubMed]
[7] Shi, Z., Pang, K., Wu, Z., Dong, Y., Hao, L., Qin, J., et al. (2023) Tumor Cell Plasticity in Targeted Therapy-Induced Resistance: Mechanisms and New Strategies. Signal Transduction and Targeted Therapy, 8, Article No. 113. [Google Scholar] [CrossRef] [PubMed]
[8] Kong, W., Gao, Y., Zhao, S. and Yang, H. (2023) Cancer Stem Cells: Advances in the Glucose, Lipid and Amino Acid Metabolism. Molecular and Cellular Biochemistry. [Google Scholar] [CrossRef] [PubMed]
[9] Paul, R., Dorsey, J.F. and Fan, Y. (2022) Cell Plasticity, Senescence, and Quiescence in Cancer Stem Cells: Biological and Therapeutic Implications. Pharmacology & Therapeutics, 231, Article ID: 107985. [Google Scholar] [CrossRef] [PubMed]
[10] Izadpanah, A., Mohammadkhani, N., Masoudnia, M., Ghasemzad, M., Saeedian, A., Mehdizadeh, H., et al. (2023) Update on Immune-Based Therapy Strategies Targeting Cancer Stem Cells. Cancer Medicine, 12, 18960-18980. [Google Scholar] [CrossRef] [PubMed]
[11] Awasthi, S., Ahmad, S., Gupta, R., et al. (2023) Differential Expression of Cancer Stem Cell Markers and Pro-Inflammatory Cytokine IL-1β in the Oral Squamous Cell Carcinoma and Oral Submucosal Fibrosis. International Journal of Health Sciences (Qassim), 17, 28-38.
[12] Escudero Mendez, L., Srinivasan, M., Hamouda, R.K., Ambedkar, B., Arzoun, H., Sahib, I., et al. (2022) Evaluation of CD44+/CD24− and Aldehyde Dehydrogenase Enzyme Markers in Cancer Stem Cells as Prognostic Indicators for Triple-Negative Breast Cancer. Cureus, 14, e28056. [Google Scholar] [CrossRef] [PubMed]
[13] Gómez-Gallegos, A.A., Ramírez-Vidal, L., Becerril-Rico, J., Pérez-Islas, E., Hernandez-Peralta, Z.J., Toledo-Guzmán, M.E., et al. (2023) CD24+CD44+CD54+EpCAM+ Gastric Cancer Stem Cells Predict Tumor Progression and Metastasis: Clinical and Experimental Evidence. Stem Cell Research & Therapy, 14, Article No. 16. [Google Scholar] [CrossRef] [PubMed]
[14] Chen, Q., Gu, M., Cai, Z., Zhao, H., Sun, S., Liu, C., et al. (2020) TGF-β1 Promotes Epithelial-to-Mesenchymal Transition and Stemness of Prostate Cancer Cells by Inducing PCBP1 Degradation and Alternative Splicing of CD44. Cellular and Molecular Life Sciences, 78, 949-962. [Google Scholar] [CrossRef] [PubMed]
[15] Dhar, D., Antonucci, L., Nakagawa, H., Kim, J.Y., Glitzner, E., Caruso, S., et al. (2018) Liver Cancer Initiation Requires P53 Inhibition by CD44-Enhanced Growth Factor Signaling. Cancer Cell, 33, 1061-1077.e6. [Google Scholar] [CrossRef] [PubMed]
[16] Okuyama, H., Nogami, W., Sato, Y., Yoshida, H., Tona, Y. and Tanaka, Y. (2019) Characterization of CD44-Positive Cancer Stem-Like Cells in COLO 201 Cells. Anticancer Research, 40, 169-176. [Google Scholar] [CrossRef] [PubMed]
[17] Boman, B.M., Viswanathan, V., Facey, C.O.B., Fields, J.Z. and Stave, J.W. (2023) The V8-10 Variant Isoform of CD44 Is Selectively Expressed in the Normal Human Colonic Stem Cell Niche and Frequently Is Overexpressed in Colon Carcinomas during Tumor Development. Cancer Biology & Therapy, 24, Article ID: 2195363. [Google Scholar] [CrossRef] [PubMed]
[18] Huang, Q., Liu, L., Xiao, D., Huang, Z., Wang, W., Zhai, K., et al. (2023) CD44+ Lung Cancer Stem Cell-Derived Pericyte-Like Cells Cause Brain Metastases through GPR124-Enhanced Trans-Endothelial Migration. Cancer Cell, 41, 1621-1636.e8. [Google Scholar] [CrossRef] [PubMed]
[19] Fernández-Tabanera, E., García-García, L., Rodríguez-Martín, C., Cervera, S.T., González-González, L., Robledo, C., et al. (2023) CD44 Modulates Cell Migration and Invasion in Ewing Sarcoma Cells. International Journal of Molecular Sciences, 24, Article No. 11774. [Google Scholar] [CrossRef] [PubMed]
[20] Zhang, H., Cao, H., Luo, H., Zhang, N., Wang, Z., Dai, Z., et al. (2023) RUNX1/CD44 Axis Regulates the Proliferation, Migration, and Immunotherapy of Gliomas: A Single-Cell Sequencing Analysis. Frontiers in Immunology, 14, Article ID: 1086280. [Google Scholar] [CrossRef] [PubMed]
[21] Liu, S., Liu, Z., Shang, A., Xun, J., Lv, Z., Zhou, S., et al. (2023) CD44 Is a Potential Immunotherapeutic Target and Affects Macrophage Infiltration Leading to Poor Prognosis. Scientific Reports, 13, Article No. 9657. [Google Scholar] [CrossRef] [PubMed]
[22] Ma, J., Wu, R., Chen, Z., Zhang, Y., Zhai, W., Zhu, R., et al. (2023) CD44 Is a Prognostic Biomarker Correlated with Immune Infiltrates and Metastasis in Clear Cell Renal Cell Carcinoma. Anticancer Research, 43, 3493-3506. [Google Scholar] [CrossRef] [PubMed]
[23] Hou, W., Kong, L., Hou, Z. and Ji, H. (2022) CD44 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Gastric Cancer. BMC Medical Genomics, 15, Article No. 225. [Google Scholar] [CrossRef] [PubMed]
[24] Martins Gama, J., Caetano Oliveira, R., Teixeira, P., Silva, F., Abrantes, C., Figueiredo, P., et al. (2023) An Immunohistochemical Study of Breast Cancer Brain Metastases: The Role of CD44 and AKT in the Prognosis. Applied Immunohistochemistry & Molecular Morphology, 31, 318-323. [Google Scholar] [CrossRef] [PubMed]
[25] Jakob, M., Sharaf, K., Schirmer, M., Leu, M., Küffer, S., Bertlich, M., et al. (2020) Role of Cancer Stem Cell Markers ALDH1, BCL11B, BMI-1, and CD44 in the Prognosis of Advanced HNSCC. Strahlentherapie und Onkologie, 197, 231-245. [Google Scholar] [CrossRef] [PubMed]

为你推荐